CAPE

A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients with Moderately to Severely Active Crohn's Disease (CD)
evaluate long-term safety of Humira in pediatric patients (between the ages of 6 and 17 years inclusive at the time of enrollment) with moderately to severely active CD who are prescribed and treated in accordance with the approved local Humira product label under the conditions of routine clinical setting
CHLA IRB Number
CHLA-15-00250
Study Type
Observational
Eligibility
Ages of 6 through 17 years inclusive at the time of enrollment, diagnosed
with moderately to severely active CD who has been prescribed Humira therapy
Enrollment Status
Closed
Does this study also recruit healthy volunteers?
No
Coordinator Contact
Sharon Tang
Contact Email
shatang@chla.usc.edu